Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, a population-scale biobank initiative.

Under the collaboration, Thermo Fisher will deploy proteomics technologies including its Olink Proximity Extension Assay platforms and the Orbitrap Astral mass spectrometry system. The technologies will be used alongside Seer's Proteograph Product Suite to analyze protein data from the study participants.

The PRECISE-SG100K study has completed recruitment of over 100,000 participants from Singapore's population. The research aims to monitor long-term health outcomes and identify factors associated with diseases including diabetes, hypertension and cancer.

"Proteomics at population scale represents one of the most powerful opportunities to understand disease in real time across the full continuum of health," said Marc N. Casper, chairman and chief executive officer of Thermo Fisher.

The study integrates multiple proteomic technologies across a longitudinal population cohort. Thermo Fisher stated this approach is designed to strengthen reproducibility and support evidence generation for regulatory purposes.

Thermo Fisher currently supports other large-scale biobank initiatives including the UK Biobank Pharma Proteomics Project, FinnGen in Finland, and Geisinger's MyCode Community Health Initiative in the United States. The company reported these programs collectively encompass analyses of more than one million samples.

The collaboration includes Seer, Inc. as a research partner and Novogene, which provides laboratory services for sample processing and data generation. The information is based on a company press release.